Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
5 hedge funds and large institutions have $94K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2016 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
69% less capital invested
Capital invested by funds: $304K → $94K (-$210K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$8.15K |
EYEGW Hedge Fund Activity: Q2 2016 in Review
5 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q2 2016, worth a combined $94K — down 69% from $304K a quarter earlier.
Fund positioning in EYEGW was balanced in Q2 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Sabby Management, cutting an estimated $8.15K.
- 5 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $94K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q2 2016, down 69% quarter-over-quarter.
- 0 funds opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q2 2016 and 0 closed out.
- The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q2 2016 was Sabby Management, an estimated $8.15K sold.
Based on aggregated 13F filings for Q2 2016.